Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 14/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ditekiren SCHEMBL30671592 | 0.92 | REN (0.84) | REN | |
| SCHEMBL29483353 | 0.83 | REN (0.84) | REN | |
| SCHEMBL9755311 | 0.69 | REN (0.67) | REN | |
| SCHEMBL28067689 | 0.66 | TRHR (0.52) | REN | |
| SCHEMBL9754023 | 0.66 | REN (0.62) | REN | |
| SCHEMBL9754021 | 0.66 | REN (0.62) | REN | |
| SCHEMBL14008234 | 0.65 | REN (0.49) | REN | |
| SCHEMBL30305967 | 0.65 | REN (0.92) | REN | |
| SCHEMBL10464551 | 0.65 | REN (0.65) | REN | |
| SCHEMBL9640485 | 0.65 | REN (0.54) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1644 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082608-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2025-03-13 | — | — | US | claimed |
| EP-4448096-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | Singapore Health Services Pte. Ltd. (SG) | 2024-10-23 | — | — | EP | claimed |
| WO-2023111196-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE. LTD. (SG) | 2023-06-22 | — | — | WO | claimed |
| WO-2020018785-A1 | METHODS OF TREATING ANGIOEDEMA | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2020-01-23 | — | — | WO | claimed |
| EP-2661431-B1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2018-07-11 | — | — | EP | claimed |
| US-9526711-B2 | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-12-27 | — | — | US | claimed |
| US-20160279086-A1 | BIPHENYL-3-CARBOXYLIC ACID MODULATORS OF BETA-3-ADRENORECEPTOR | AUSPEX PHARMACEUTICALS INC (US) | 2016-09-29 | — | — | US | claimed |
| US-9394239-B2 | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | claimed |
| US-9029407-B2 | Aminothiazole modulators of beta-3-adrenoreceptor | AUSPEX PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2005116000-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2005-12-08 | — | — | WO | claimed |
| WO-2005116016-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2005-12-08 | — | — | WO | claimed |
| WO-2005113506-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2005-12-01 | — | — | WO | claimed |
| WO-2005113519-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2005-12-01 | — | — | WO | claimed |
| CN-1655819-A | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic | NOVARTIS AG (CH) | 2005-08-17 | — | — | CN | claimed |
| EP-1531879-A1 | USE OF ORGANIC COMPOUNDS | Novartis AG (CH) | 2005-05-25 | — | — | EP | claimed |
| US-20040266743-A1 | Combination of an aldosterone receptor antagonist and a renin inhibitor | PHARMACIA CORPORATION | 2004-12-30 | — | — | US | claimed |
| WO-2004100871-A2 | COMBINATION OF AN ALDOSTERONE RECEPTOR ANTAGONIST AND A RENIN INHIBITOR | PHARMACIA CORPORATION (US) | 2004-11-25 | — | — | WO | claimed |
| WO-2004002549-A1 | USE OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2004-01-08 | — | — | WO | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266743-A1 | Combination of an aldosterone receptor antagonist and a renin inhibitor | REN, AGTR1, AGTR2 | REN 1/4885 |
| US-20160279086-A1 | BIPHENYL-3-CARBOXYLIC ACID MODULATORS OF BETA-3-ADRENORECEPTOR | ADRB3, ADRB1, ADRA2C | REN 358/4885 |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | CACNA1G, CACNA1F, CACNA1H | REN 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.